BlueReg reinforce further its European footprint by opening a new office in Zug, Switzerland

BlueReg Pharma Consulting Early Access Program

1 September 2021

BLUEREG GROUP

BlueReg the international regulatory consultancy organization for life sciences companies, is announcing the expansion of its commercial presence in Europe by opening its eighth office worldwide, and this time in Zug, Switzerland.

 

Located in a key pharmaceutical center at Baarerstrasse 14, this new office aims to bring BlueReg closer to its existing clients located in Switzerland as well as prospective clients setting up operations in this location as to identify new business opportunities, and to develop its commercial presence in Europe.

 

“Following expansion in the United States, we are excited to continue our growth in Europe. The opening of this new commercial office in Zug reinforce our ambition to develop BlueReg internationally.” says Corinne Schmitz, CEO of BlueReg Group.

 

About BlueReg

 

BlueReg is a consulting and service company specializing in life sciences and regulatory affairs. It offers strategic advice and hands-on / outsourcing solutions to life sciences companies, through the entire lifecycle of their products, from product development, registration through to launch, and product maintenance activities. BlueReg partners with biotech start-ups and pharmaceutical companies to accelerate the access of their innovative medicines to patients through early access programs and this before obtaining an MA (Marketing Authorization) in Europe.

 

To follow our latest news, follow us on our social media https://www.linkedin.com/company/bluereg-group and www.twitter.com/bluereggroup

 

Press Contact:

Nicolas Schmitz

Expansion & Marketing Strategy

schmitz.nicolas@blue-reg.com

BLUEREG GROUP

Did you like this article? Share on social networks:

Associated News

How to take advantage of early access programs for your innovative treatments in France?

Known as Expanded Access Programs in the US, early access programs (EAP) allow access to...

Learn more

Benefits of using a third party Exploitant to run early access programs in France and more

Main benefits of outsourcing "Exploitant" status : Reminder : French regulatory authorities require having an...

Learn more

Consulting Regulatory Affairs Services for Pharmaceutical companies

  The regulatory affairs process is a critical component of the safe development, registration and...

Learn more